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Abstract: Kidney involvement with progressive loss of kidney function (Fabry nephropathy) 
is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising 
from deﬁ  ciency of α-galactosidase activity. Clinical trials have shown that enzyme replacement 
therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from 
kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry 
nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt 
proteinuria do not respond as well to ERT alone, but can beneﬁ  t from anti-proteinuric therapy 
given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy 
with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results 
are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of 
adjunctive agents to control urinary protein excretion, and the individual factors that affect 
disease severity are reviewed.
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Introduction
Johannes Fabry and William Anderson independently ﬁ  rst described this disorder in 
1898 (Fabry 2001). They described patients with “angiokeratoma corporis diffusum”, 
the red-purple maculopapular skin lesions that are characteristic of the disease. 
After these initial cases, other associated symptoms were described and eventually 
mutations in the alpha-galactosidase A (AGAL) gene were found to be responsible 
for the disease (Brady et al 1967), which is an X-linked disorder of glycosphingolipid 
metabolism. This defect results in alpha-galactosidase A deﬁ  ciency, with progressive 
accumulation of neutral glycosphingolipids, (predominately globotriaosylceramide; 
GL-3) in lysosomes, as well as other cellular compartments and the extracellular 
space (Askari et al 2007). For Fabry disease, the incidence/prevalence ranges from 
1 in 40,000 to 1:117,000 in the US and Australia to 1:833,000 in northern Portugal, 
the majority of them Caucasians (Meikle et al 1999). These ﬁ  gures may underestimate 
the real prevalence of the disease as many patients go undiagnosed due to rarity of this 
disorder, and phenotypic variation of the clinical features that can be marked, especially 
in females. Much higher estimates of prevalence (eg, 1 in 4,000) have been obtained 
with a newborn screening project (Spada et al 2006). Most affected males have little, 
if any, alpha-galactosidase A activity, and the deposition of GL-3 occurs primarily 
in vascular endothelial cells as well as epithelial and smooth muscle cells through-
out the body. Early clinical manifestations of the disease include angiokeratoma, 
acroparesthesias, episodic pain “crises”, hypohydrosis, and gastrointestinal complaints 
(Desnick et al 2001).
With time, progressive GL-3 accumulation in the microvasculature and 
parenchyma leads to microvascular dysfunction, occlusion, and ischemia. Recent 
reports have described increased oxidative stress (Shen et al 2008), and circulating Biologics: Targets & Therapy 2008:2(4) 824
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myeloperoxidase in Fabry disease, which appears to be 
associated with vasculopathic events in male patients 
(Kaneski et al 2006). The renal, cardiovascular, and 
cerebrovascular manifestations such as proteinuria, chronic 
kidney disease and kidney failure, cardiac arrhythmias, 
hypertrophic cardiomyopathy, and strokes can lead to early 
death during the fourth and ﬁ  fth decade of life in affected 
males (Desnick et al 2001; Branton et al 2002). Kidney 
involvement in Fabry disease is expressed at an earlier age 
in hemizygous males than in heterozygous females (Gupta 
et al 2005; Kobayashi et al 2008; Ortiz et al 2008; Wilcox 
et al 2008). Ultimately, end-stage renal disease (ESRD) 
develops in males in the third to ﬁ  fth decades of life (Desnick 
et al 2001; Branton et al 2002), although ESRD developing 
in the second decade has been reported in males (Sheth et al 
1983). Females also can progress to ESRD, but generally at 
a latter age than in males (Wilcox et al 2008).
Clinical presentation and spectrum
of Fabry disease
Patients with Fabry disease presenting only with kidney 
involvement are rare, and only a few cases have been 
described (Sawada et al 1996; Nakao et al 2003; Rosenthal 
et al 2004). Nakao et al screened 514 unselected Japanese 
male hemodialysis patients, and identiﬁ  ed 6 patients with 
Fabry disease, a prevalence rate of 1.2% (Nakao et al 2003). 
Among the cases reported by Nakao et al one had classic 
Fabry disease that had been overlooked, and 5 patients 
lacked the “classical” manifestations of angiokeratoma, 
acroparesthesias, hypohidrosis, and ocular opacities. While 
one patient had a novel mis-sense mutation (G373D), the 
others had mutations that were previously described in 
“classical” cases. Five of the patients (Nakao et al 2003) 
had left ventricular hypertrophy, and 1 had a normal 
echocardiogram. It appears that the kidney and heart are 
frequently involved in Fabry disease. There are overlap-
ping ﬁ  ndings between the so-called “cardiac” and “renal” 
variants (Germain 2001; Nakao et al 2003; Hauser et al 2004; 
Meehan et al 2004; Fervenza et al 2008); most patients with 
the cardiac variant also have kidney involvement (Mehta 
et al 2004). The “cardiac” variant of Fabry disease refers 
to patients who have some residual alpha-galactosidase 
A activity, with GL-3 deposition conﬁ  ned to myocytes, and 
as ﬁ  rst described, do not manifest the whole spectrum of 
symptoms present in classical Fabry disease (von Scheidt 
et al 1991; Nakao et al 1995). Clinical presentation is usu-
ally in the ﬁ  fth to the eighth decade with left ventricular 
hypertrophy, mitral insufﬁ  ciency, and cardiomyopathy and 
ventricular ectopy (Takenaka et al 2008). It is sobering 
to note that even with some residual alpha-galactosidase 
A activity, these patients still develop cardiomyopathy and 
die with congestive heart failure.
These considerations emphasize the phenotypic variation 
that can be observed in Fabry disease, even in male patients, 
and also illustrates the limitations of the term “classical” for 
describing the presentation of an individual patient. Similarly, 
use of single organ “variant” descriptions emphasizes major 
organ involvement at the ﬁ  rst assessment, but does not 
recognize the progressive nature of multi-organ involvement 
in Fabry disease.
Attempting to correlate the genotype to phenotypic 
variations is not straightforward. Many female and some 
male patients have minimal disease manifestations during 
most of their life. Residual alpha-galactosidase A activity 
as well as other genetic factors may affect the phenotype. 
Due to non-random X inactivation, females appear to 
have greater phenotypic variation than male patients with 
the same mutation (Desnick et al 2001; Whybra et al 
2001; Gupta et al 2005; Deegan et al 2006; Wilcox et al 
2008). Modifying genes may include those involved in 
glycolipid metabolism, which may increase the availability 
of substrates for alpha-galactosidase A, thus increasing 
the disease severity. It has been suggested that a deacyla-
tion product of GL-3 may modify disease severity (Aerts 
et al 2008). Polymorphisms in the 5’-untranslated region 
could affect the afﬁ  nity for transcription enhancers and 
thereby affect AGAL transcription, which could explain 
altered enzyme activity and even tissue-speciﬁ  c phenotypic 
expression of Fabry disease in rare patients for whom coding 
region or splice-site mutations cannot be readily identiﬁ  ed 
(Oliveira et al 2008).
Kidney involvement in Fabry disease
Since Fabry disease is a potentially treatable condition it is 
imperative to consider it in the differential diagnosis of any 
patient presenting with progressive chronic kidney disease 
(CKD) and proteinuria, especially if the blood pressure is 
not elevated and there is a family history of kidney disease. 
While Fabry disease may not lead the differential diagnosis 
list, the clinical indications for kidney biopsy are clearly 
fulﬁ  lled, and the results should readily lead to the correct 
diagnosis, even if it was not suspected before the procedure. 
The typical manifestations of Fabry nephropathy on biopsy 
are well described and readily appreciated, so the diagnosis 
should be readily discerned (Gubler et al 1978; Sessa et al 
2002; Fervenza et al 2008).Biologics: Targets & Therapy 2008:2(4) 825
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Two patient registries are now available (Fabry Registry 
and Fabry Outcome Survey), which contain detailed 
descriptions of individual patient status. Baseline assessments 
of age and estimated glomerular ﬁ  ltration rate (eGFR) for 
585 adult male and 677 adult female patients from the Fabry 
Registry have been published (Ortiz et al 2008). Thirteen 
percent of adult females, and 28% of adult males had 
eGFR   60 mL/min/1.73 m2 at their baseline evaluations 
before starting enzyme replacement therapy (ERT). Figure 1 
(Ortiz et al 2008) illustrates the magnitude of proteinuria at 
the time of baseline evaluation for 300 male (top panel) and 
306 female (bottom panel) members of the Fabry Registry 
cohort for whom these data were available. The horizontal 
lines represent the median level of proteinuria, and the 
vertical lines represent the median eGFR. Overt proteinuria 
is present at the ﬁ  rst evaluation in the majority of patients, 
throughout the entire range of eGFR.
Enzyme replacement therapy (ERT)
Until recently, recognition of Fabry disease did not affect 
the patient’s prognosis, since no treatment was available. 
However, the availability of ERT with recombinant 
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Figure 1 Distribution of proteinuria and eGFR. The median values for eGFR are shown as vertical lines, and the median 24-h urine protein is shown as horizontal lines in both panels. 
A) Males, n = 300, median eGFR = 81.0 mL/min/1.73 m2, and median proteinuria = 572 mg/24 h. B) Females, n = 306, median eGFR = 88.0 mL/min/1.73 m2, and median proteinuria = 
180 mg/24 hr. Data from the Fabry Registry reproduced with permission from Ortiz A, Oliveira JP, Waldek S, et al 2008. Nephropathy in males and females with Fabry disease: 
cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant, 23:1600–7. Copyright © 2008 Oxford University Press.Biologics: Targets & Therapy 2008:2(4) 826
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alpha-galactosidase A offers the promise of altering 
the natural history of this rare form of proteinuric CKD 
(Schiffmann 2007; Warnock 2007).
Currently, there are two forms of ERT available for the 
treatment of Fabry disease: (1) Replagal® (agalsidase-alfa; 
Shire Human Genetic Therapies, Inc., Cambridge, MA) and 
(2) Fabrazyme® (agalsidase-beta; Genzyme Corporation, 
Inc., Cambridge, MA). With the exception of the structures 
of the oligosaccharide side chains, the primary amino acid 
sequences of these products are the same (Blom et al 2003). 
The approved doses of agalsidase-alfa and agalsidase-beta are 
0.2 mg/kg and 1.0 mg/kg, given intravenously every 2 weeks, 
respectively. Agalsidase-beta has been approved for the 
treatment of Fabry disease in the US, while both agents 
are available for clinical use in other countries (Desnick 
2004). The overall experience with ERT has been very 
encouraging (Barbey et al 2008). Figure 2 illustrates the 
effect of ERT in a male Fabry patient with moderately 
severe nephropathy in whom proteinuria was controlled 
with irbesartan (De Schoenmakere et al 2003); the rate of 
loss of kidney function was reduced by 67%. Earlier reports 
with agalsidase-alfa given at 0.2 mg/kg every other week to 
male Fabry patients with relatively mild disease were also 
encouraging (Barbey et al 2008).
Placebo-controlled trials of ERT
Agalsidase-alfa phase III trial
The first double-blind, placebo controlled trial with 
agalsidase-alfa at 0.2 mg/kg given every 2 weeks for 24 weeks 
was carried out in 24 “classically affected” adult male 
Fabry patients, with average age of 34.2 years, and creati-
nine clearance of 96 mL/min (Schiffmann et al 2001). The 
primary outcome measure, reduction in neuropathic pain “at 
its worst, without pain medications”, was improved in the 
13 active-treatment patients compared to the placebo-treated 
controls. Secondary outcome measures included stabilization 
of creatinine and inulin clearances in the active-treatment 
group, while the placebo-controlled group of 11 patients 
had approximately 18% decreases in their kidney function. 
Baseline urine protein excretion exceeded 1 g/day in 5 of the 
active-treatment group and 3 of the placebo-treated group. 
Mesangial widening decreased by 12.5% in kidney biopsies 
evaluated before and after 24 weeks of agalsidase-alfa ther-
apy, and increased by 16.5% in the placebo-treated patients. 
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Figure 2 Effects of agalsidase-beta on rate of loss of kidney function in a 36-year-old male with Fabry nephropathy. Creatinine clearance was measured at the indicated points, 
and enzyme replacement therapy (1 mg/kg every 2 weeks) was started in early 2001. During the entire follow-up period, there were no major changes in blood pressure or 
proteinuria (0.4–0.6 g). The patient was started on 5 mg lisinopril in 1994. Because of persistent cough, irbesartan at 150 mg/day was substituted in for lisinopril in December 
2001. Reproduced with permission from De Schoenmakere G, Chauveau D, Grunfeld JP. 2003. Enzyme replacement therapy in Anderson-Fabry’s disease: beneﬁ  cial clinical effect 
on vital organ function. Nephrol Dial Transplant, 18:33–5. Copyright © 2003 Oxford University Press.Biologics: Targets & Therapy 2008:2(4) 827
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Surprisingly, there was a signiﬁ  cant increase in the segmen-
tal sclerosis scores for the active-treatment group after 24 
weeks. This effect may have reﬂ  ected the presence of overt 
proteinuria in 5 of the active-treated patients. There was no 
effect on proteinuria observed with 24 weeks of agalsidase-
alfa therapy.
Most (8/14) of the active-treatment patients had mild 
infusion-related reactions, and 12/14 developed IgG antibodies 
to agalsidase. Plasma GL-3 decreased in the active-treatment 
group, and was unchanged in the placebo-treated group. 
Urinary GL-3 decreased by 29% in the active-treatment group, 
and increased by 15.4% in the placebo-treated patients.
Agalsidase-beta phase III trial
Results of a multi-center double blind phase III trial in 
which 58 patients (average age 30.2 years, 56 males) were 
randomized to agalsidase-beta or placebo for 20 weeks 
followed by 6 months open-label treatment (Eng et al 2001). 
The primary outcome measure was reduction in GL-3 
accumulation scores to zero in renal interstitial capillaries. 
Twenty out of 29 patients (69%) in the agalsidase-beta 
treatment group, and none of the placebo-treated patients 
achieved complete GL-3 clearance from their renal 
interstitial capillaries (p   0.001). Six of the other 9 active 
treatment group patients showed substantial but not complete 
improvement in their GL-3 accumulation scores.
Secondary outcome measures included reduction of 
microvascular endothelial deposits in heart, kidney and skin, 
change in baseline urinary GL-3 excretion and kidney GL-3 
content, and reduction in pain scores. The overall composite 
score for microvascular endothelial GL-3 accumulation 
decreased from 4.9 ± 1.5 at baseline to 0.7 ± 0.8 at week 
20 (85.7% decrease). The baseline GFR measured with inulin 
clearance was 83 ml/min in the active-treatment group, and 
96.6 mL/min in the placebo-treatment group at baseline. 
Kidney function did not signiﬁ  cantly change in either group 
at the end of the 24-week double-blind study (p   0.19), or 
after 6 months of open label treatment (p   0.81). Fifty nine 
percent of the active-treated group had mild infusion related 
reactions, and 88% had IgG seroconversion. Plasma GL-3 
decreased to normal levels by week 14 in the active-treated 
group, and did not change in the placebo-treated group. 
Urinary GL3 decreased by 34.1% in the active-treatment 
group, and by 6.2% in the placebo-treatment group.
Agalsidase-beta phase IV trial
Results of a multi-center double-blind phase IV trial in which 
82 adult patients with initial GFR values   80 mL/min/1.73 m2 
who were randomized (2:1) to treatment with agalsidase-beta 
at 1 mg/kg every 2 weeks or placebo have been published 
(Banikazemi et al 2007). Seventy-two patients were males, 
and the average age was 45.9 years. The median time in 
treatment was 18.5 months, and individual patients were 
treated for as long as 35 months.
The composite primary endpoint was the ﬁ  rst clinical 
event: kidney −33% increase in creatinine on 2 successive 
measures or reaching ESRD; cardiac events; central nervous 
system (CNS) events; or death. The expected event rate 
was 40% over 2 years for the placebo group, and 10% 
for the active-treatment patients. The study ended when 
approximately one third of the patients had experienced a 
total of 27 primary clinical events, 17 (63%) of which were 
accounted by sustained 33% increases in serum creatinine.
Primary endpoint analysis was conducted on the 
intention-to-treat cohort, and the secondary analyses, in a 
pre-speciﬁ  ed per-protocol population. Two deaths, 1 for 
each group, occurred after a primary endpoint (cardiac arrest, 
and cardiac arrest after stroke), and death of 1 patient (due 
to pulmonary embolism) in the agalsidase-beta group was 
the primary endpoint. Thirteen of 31 patients in the placebo 
group (41.9%) had primary outcome events (7 renal events, 
4 cardiac, 2 CNS, 0 death), and 14 of the 51 agalsidase-beta 
patients (27.4%) had primary outcome events (10 renal events, 
3 cardiac, 0 CNS, 1 death from pulmonary embolus).
There was an imbalance in the baseline proteinuria, with 
patients allocated to the ERT arm having signiﬁ  cantly greater 
baseline proteinuria than those in the placebo arm, a fact that 
complicates the interpretation of the outcome of the study 
(Schiffmann 2007). The baseline eGFR was 53.0 ± 17.7 (SD) 
in the agalsidase-beta group and 52.4 ± 17.7 (SD) in the 
placebo group. The baseline urine protein/creatinine ratio 
was 1.5 = ± 1.5 (SD) in the agalsidase-beta group, and 
1.1 ± 1.4 (SD) in the placebo group. After adjustment for 
baseline proteinuria, the intention-to-treat analysis showed 
that ERT was associated with a 53% risk reduction in the 
primary event rate, although due to the small number of 
patients in the trial the results did not reach statistically 
signiﬁ  cance (p = 0.058). Secondary analysis showed that 
the beneﬁ  t of ERT was greater in those patients with GFR 
values > 55 mL/min per 1.73 m2, and those patients with 
GFR values   55 mL/min per 1.73 m2 did not appear to 
beneﬁ  t from ERT (Banikazemi et al 2007).
Most of the treatment-related events were mild or 
moderate infusion-associated reactions (rigors and fever) that 
occurred in 55% of patients in the agalsidase-beta group and 
23% of the placebo-treated group, and were more common Biologics: Targets & Therapy 2008:2(4) 828
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during the ﬁ  rst 6 months of treatment. One patient in the 
agalsidase-beta group experienced severe hypotension and 
had a positive serum IgE test result. Forty-three patients 
(68%) developed IgG antibodies against recombinant 
agalsidase-beta. Plasma GL-3 levels were reduced to normal 
by 6 months in the active-treatment group, and were main-
tained at these levels throughout the study. Urinary GL-3 
levels were not assessed.
Open label studies of ERT dose
and frequency of dosing
The effect of dosing interval with agalsidase-alfa has been 
examined (Schiffmann et al 2007); a group of adult males 
patients who had progressive decline in eGFR despite 2 to 4 
years of 0.2 mg/kg agalsidase-alpha therapy every other 
week, were 0.2 mg/kg agalsidase-alfa every week. (It should 
be noted that this is an “off-label” use of agalsidase-alfa.) 
Before switching to weekly dosing, the mean decline in eGFR 
was −8.0 ± 2.8 (SD) mL/min/1.73 m2/year. Four patients with 
low baseline proteinuria (average = 222.8 ± 60 [SD] mg/day) 
progressed on agalsidase-alfa given every other week at a 
rate of −6.6 ± 2.1 mL/min/1.73 m2 per year. After switching 
to weekly dosing of agalsidase-alfa, these 4 patients had 
an improvement in their kidney function (Figure 3). The 
remaining patients with higher baseline proteinuria levels 
had some improvement in the rate of decline of their kidney 
function, but still progressed at a rate of −5.5 ± 4.2 (SD) 
mL/min/1.73 m2 per year on 0.2 mg/kg agalsidase-alfa given 
on a weekly basis (Figure 3).
A similar experience with increasing the dose of 
agalsidase-alfa from 0.2 mg/kg every other week to 0.4 mg/kg 
every other week in an off-label, compassionate-use basis has 
been described (Torra et al 2008). This patient had baseline 
proteinuria that ranged from 1 to 3 g/day, and developed 
moderately severe Fabry nephropathy with a progression 
rate of −7.7 ± 1.2 mL/min/1.73 m2/year before the institution 
of ERT (Figure 4). No signiﬁ  cant effect on kidney function 
was seen with agalsidase-alfa given at 0.2 mg/kg, and when 
the dose was increased (off-label, compassionate use) to 
0.4 mg/kg every other week, the progression rate slowed 
to −3.7 ± 0.6 mL/min/1.73 m2/year. While consistent with 
a dose-effect of ERT on progression, this effect was also 
confounded by overt proteinuria of 2.7 ± 0.5 g/day during 
the period of agalsidase-alfa administration at 0.2 mg/kg 
every 2 weeks and reduced proteinuria associated with ACEI 
therapy during the later phase.
Another case report (Warnock 2005) reached a similar 
conclusion with respect to the dosing of ERT in moderately 
severe Fabry nephropathy. This patient was initially treated 
with agalsidase-alfa; despite anti-proteinuric therapy with 
enalapril and losartan to control proteinuria before ERT 
was started, and at an average 0.83 ± 0.54 g/day during the 
administration of ERT at 0.2 mg/kg every other week, there 
was rapid progression at −13.7 ± 1.5 mL/min/1.73 m2/year 
during the 16 months of treatment with agalsidase-alfa 
(Figure 5). This patient was then switched to agalsidase-beta 
in May 2003, and was the ﬁ  rst patient to receive commercially 
available ERT in the US (Warnock 2005). This patient 
progressed rapidly on agalsidase-alfa (0.2 mg/kg every other 
week) despite control of his proteinuria with ACEI/ARB 
therapy before ERT was instituted (Figure 5), suggesting 
that control of proteinuria is necessary but not sufﬁ  cient 
for controlling progressive loss of eGFR in moderately 
severe Fabry nephropathy, and should not be considered 
as a treatment alternative to the initiation of ERT in Fabry 
nephropathy.
An open-label extension study of the phase IV study 
with agalsidase-beta has been completed, but the results 
have not yet been published. In post-hoc analysis of the 
original phase IV report, an apparent beneﬁ  t of ERT with 
agalsidase-beta at 1 mg/kg every 2 weeks was observed in 
patients with baseline eGFR   55 ml/min/1.73 m2; there was 
a 75% reduction in the hazard ratio compared to placebo for 
reaching the primary endpoint (Banikazemi et al 2007). It is 
important to know if the renal protective effect of ERT was 
maintained throughout the 18-month follow-up period of 
Figure 3 Annualized change in estimated glomerular ﬁ  ltration rate (mL/min/1.73 
m2/year ± SD) in patients treated with agalsidase-alfa at 0.2 mg/kg every 2 weeks (left 
bars) followed by weekly treatment (right bars). Patients are stratiﬁ  ed by baseline 
proteinuria:  0.3 g/day, black bars;  1 g/day, open bars. Adapted with permission 
from Schiffmann R, Askari H, Timmons M, et al 2007. Weekly enzyme replacement 
therapy may slow decline of renal function in Fabry patients who are on long-term 
biweekly dosing. J Am Soc Nephrol, 18:1576–83. Copyright © 2007 American Society 
of Nephrology.
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the phase IV extension study. Similar long-term follow up 
studies of the patients enrolled in the agalsidase-alfa studies 
would also be of great interest.
Endothelial GL-3 clearance
and the effects of ERT
Randomized, placebo-controlled trials and long-term, 
open-label extension studies of both products have 
consistently demonstrated that ERT reduces GL-3 levels in 
plasma and urine as well as glycosphingolipids accumulation 
in capillary endothelial cells, renal glomerular cells, and 
tubular epithelial cells (Schiffmann et al 2001; Thurberg et al 
2002), although the extent of clearance may be greater with 
the larger doses of ERT. A detailed examination of the effects 
of ERT on GL-3 deposits in various kidney cell types has 
been described by Thurburg et al (Thurberg et al 2002).
An example of severe GL-3 deposits in the glomerular 
capillary endothelial cells of a patient with severe Fabry 
nephropathy (baseline eGFR = 25 ml/min/1.73 m2; baseline 
proteinuria = 3.4 g/day in September, 2006), and the complete 
resolution of the endothelial deposits after 14 months of ERT 
with agalsidase-beta at 1 mg/kg every 2 weeks is shown 
in Figure 6. The glomerular epithelial cells still contain 
lamellar inclusions; these are minimally cleared of GL-3 
even after extended course of ERT (Germain et al 2007). 
An autopsy report conﬁ  rms the complete clearance of vas-
cular endothelial GL-3 in a male treated with agalsidase-
beta for 2 years (Schiffmann et al 2005). Also notable in 
Figure 6D is effacement of the epithelial foot processes, as 
has been recently described (Valbuena et al 2008), while 
after 15 months of ERT, and reduction of proteinuria with 
ACEI/ARB therapy, the foot processes appear to have been 
restored.
Is there a dose-dependent effect of ERT on capillary 
endothelial GL-3 clearance? Systematic studies with doses 
less than 1 mg/kg given every 2 weeks have not been reported 
in detail. Schiffmann et al reported a “decrease in glycolipid 
inclusions within vascular endothelium” in a group of male 
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Figure 4 Annualized progression rate of change in estimated glomerular ﬁ  ltration rate (mL/min/1.73 m2/year ± SD) for a male patient before ERT, and during treatment with 
agalsidase-alfa at 0.2 mg/kg every 2 weeks, followed by treatment with agalsidase-alfa at 0.4 mg/kg every 2 weeks. The progression slope was reduced in half with the higher 
dose of ERT.   The urine protein excretion averaged 1.98 ± 0.03 (SD) g/24 h before ERT, 2.72 ± 0.52 (SD) g/24 h during ERT at 0.2 mg/kg every other week, and 1.17 ± 0.22 (SD) 
g/24 h during ERT at 0.4 mg/kg every other week along with enalapril at 5 mg 3 times per day. Adapted with permission Torra R, Algaba F, Ars E, et al 2008. Preservation of renal 
function in a patient with Fabry nephropathy on enzyme replacement therapy. Clin Nephrol, 69:445–9. Copyright © 2008 Dustri-Verlag.Biologics: Targets & Therapy 2008:2(4) 830
Fervenza et al
patients treated with 0.2 mg/kg agalsidase-alfa every 2 weeks 
for 24 weeks (Schiffmann et al 2001), but the extent of the 
reduction was not speciﬁ  ed, and complete clearing of GL-3 
deposits was not described (Schiffmann et al 2001). Several 
patients have been reported in which the kidney biopsies 
show persisting glomerular capillary endothelial GL-3 
deposits despite ERT with 0.2 mg/kg given every 2 weeks. 
Figure 7 shows 3 such cases, one treated with 0.2 mg/kg 
given every 2 weeks for 16 months, another for 24 months, 
and another for 60 months. The red circles localize what 
appear to be persisting, dense endothelial deposits of GL-3. 
In contrast, the capillary endothelial cells seen in Figure 7 
do not have such deposits after 14 months of agalsidase-beta 
therapy given at 1.0 mg/kg every 2 weeks.
Fundamental questions have to be answered before 
microvascular GL-3 clearance can be considered as a valid 
surrogate outcome marker for the treatment effects of ERT 
in Fabry disease. More information is needed about the 
relationship between the total accumulation of GL-3 and the 
burden of disease in the individual patient. Measurements of 
tissue levels of GL-3 are invasive, so more readily accessible 
samples, such as urinary GL-3 excretion are obviously 
desirable. There are some preliminary data available in the 
description of the natural history of male Fabry patients 
(Branton et al 2002) that support the interest in using GL-3 
measurements as surrogate markers for the underlying dis-
ease pathogenesis in Fabry disease. As shown in Figure 8, 
there is a relationship between the amount of GL-3 in the 
kidney, as assessed by determinations of GL-3 content in 
kidney biopsy specimens, and the severity of glomerular 
damage (Figure 8A), as well as the urinary excretion of GL-3 
(Figure 8B). Males have higher plasma and urinary levels of 
GL-3 than females, and the plasma and urinary GL-3 levels 
correlate with each other, however, there is not correla-
tion between elevated GL-3 levels and clinical symptoms 
(Vedder et al 2007). The validation of microvascular 
Figure 5 Annualized progression rate of change in estimated glomerular ﬁ  ltration rate (mL/min/1.73 m2/year ± SD) for a male patient during treatment with agalsidase-alfa at 
0.2 mg/kg every 2 weeks, followed by treatment with agalsidase-beta at 1.0 mg/kg every 2 weeks. The progression slope was reduced by 77% with the higher dose of ERT. The 
average baseline proteinuria was 2.27 ± 0.0.57 (SD) g/day before any treatment, and with added enalapril (10 mg) and losartan (50 mg), was reduced to before any ERT to 1.03 
g/day, and was maintained at an average of 0.83 ± 0.54 (SD) g/day during agalsidase-alfa treatment, and 0.56 ± 0.24 (SD) g/day during agalsidase-beta treatment. Adapted with 
permission from Warnock DG. 2005. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens, 14:87–95. Copyright © 
2005 Lippincott Williams & Wilkins.
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Figure 6 Effects of agalsidase-beta on arteriolar intimal and medial, and glomerular capillary endothelial GL-3 deposits. The patient was a 33-year-old male who was diagnosed 
with Fabry disease on the basis of the kidney biopsy ﬁ  ndings. At the time of the initial biopsy, his estimated glomerular ﬁ  ltration rate was 25 mL/min/1.73 m2, and his urine protein 
excretion was 3.3 g/24 h. His proteinuria was controlled to an average of 0.66 ± 0.44 (SD) g/24 h with 20 mg enalapril and 150 mg irbesartan, and agalsidase-beta treatment 
was started at 1.0 mg/kg every other week. The kidney biopsy was repeated after 15 months of ERT therapy. A) Renal cortical arteriole, before starting ERT (Masson-trichrome 
stain). B) Renal cortical arteriole, 15-months after starting ERT (Masson-trichrome stain); note clearing of endothelial and intimal GL-3 deposits. C) Glomerular capillary loop, 
before starting ERT (electron micrograph); note the dense endothelial deposits with substantial obliteration of the capillary lumen and the “Zebra bodies” in the podocytes. 
D) Glomerular capillary loop, 15 months after starting ERT (electron micrograph); note that the endothelial deposits have cleared, but “Zebra bodies” persist in the podocytes. 
The magniﬁ  cation is the same for A and B, but C and D have different magniﬁ  cation factors. For point of reference, the basement membrane thickness is the same for the 
electron micrographs before and after ERT. Courtesy of William Cook, MD PhD Department of Pathology, University of Alabama at Birmingham.
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Figure 7 Glomerular capillary endothelial GL-3 deposits (circled) persist despite prolonged treatment with agalsidase-alfa at 0.2 mg/kg every 2 weeks. A) 38 year old male 
after 16 months of agalsidase-alfa at 0.2 mg/kg every other week, switched to agalsidase-beta after the biopsy; estimated glomerular ﬁ  ltration rate 47 mL/min/1.73 m2, urine 
protein = 0.55 g/24 h. This patient’s clinic course is shown in Figure 7. B) 39-year-old male after 24 months of agalsidase-alfa at 0.2 mg/kg every other week, switched to agal-
sidase-alfa at 0.4 mg/kg every 2 weeks after the biopsy; estimated glomerular ﬁ  ltration rate 34 mL/min/1.73 m2, urine protein = 2.7 g/24 h. This patient’s clinic course is shown 
in Figure 8. C) 47-year-old male after 60 months of agalsidase-alfa at 0.2 mg/kg every other week, switched to agalsidase-beta at 1.0 mg/kg every 2 weeks after the biopsy; 
estimated glomerular ﬁ  ltration rate 52 mL/min/1.73 m2, urine protein = 0.41 g/24 h. This patient is the older brother of the patient shown in Figure 7 and Figure 9A. Panel A 
and C, adapted with permission from Warnock DG. 2005. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens, 
14:87–95. Copyright © 2005. Panel B, adapted with permission from Torra R, Algaba F, Ars E, et al 2008. Preservation of renal function in a patient with Fabry nephropathy on 
enzyme replacement therapy. Clin Nephrol, 69:445–9. Copyright © 2008 Dustri-Verlag.Biologics: Targets & Therapy 2008:2(4) 832
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Figure 8 Relationship between kidney GL-3 content (nmol/mg protein) and Glomerular Pathology Scores A) and urinary GL-3 excretion (nmol/g creatinine) B) The linear 
regression shown in panel A is Y = 0.505 (SE 0.0145) X −0.0959 (SE 0.3027); F statistic = 0.0021; r2 = 0.3554. The linear regression shown in panel B is Y = 71.0 (SE 27.5) X −964.8 
(SE 572.5); F statistic = 0.0169; r2 = 0.2331. Adapted with permission from Branton MH, Schiffmann R, Sabnis SG, et al 2002. Natural history of Fabry renal disease: inﬂ  uence of 
alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore), 81:122–38. Copyright © 2002 Lippincott Williams & Wilkins.
endothelial GL-3 clearance as a surrogate outcome measure 
for the clinical efﬁ  cacy of ERT is, therefore not established 
at this time. Critical issues that have to be addressed include: 
A) Are the beneﬁ  cial effects of ERT on clinical outcomes 
in Fabry nephropathy are reﬂ  ected in concordant changes 
in GL-3 load? B) Are the underlying pathophysiologic 
processes improved in parallel with reductions in the GL-3 
load? C) Are short-term changes in urinary GL-3 excretion 
of any utility is assessing response to ERT therapy? D) Do 
short-term changes in urinary GL-3 excretion reﬂ  ect changes 
in the total body GL-3 load, or just changes in renal GL-3?
The phase IV study with agalsidase-beta (Banikazemi 
et al 2007) was designed with the knowledge that there 
was nearly complete microvascular endothelial GL-3 
clearance with 1 year of ERT therapy. The primary outcome 
measures for the trial were chosen to be a composite of renal, 
cardiac and CNS events. The effect of ERT on the primary 
outcome measure did not reach statistical signiﬁ  cance for 
the per-protocal analysis. Therefore, reduction in GL-3 
inclusions did not predict clinical efﬁ  cacy, and therefore 
resolution of GL-3 did not fulﬁ  ll the criteria for a validated 
surrogate marker (Fleming 2005). The irony is that this 
surrogate marker may yet prove to be valid, but in this 
instance it was the clinical outcome study that fell short. 
The reasons for the lack of statistically signiﬁ  cancant effects 
of ERT on the primary outcome measure have been reviewed 
(Schiffmann 2007), and include insufﬁ  cient power of the 
study with only 82 participants, the differences in baseline 
proteinuria between the treatment and placebo group, and 
the failure to control protein excretion in either group with 
ACEI/ARB therapy. Despite these limitations of the phase 
IV study, Schiffmann concluded (Schiffmann 2007) that 
“…hemizygous male patients with the classic form of Fabry 
disease at possibly any age and symptomatic patients with 
milder variants should receive ERT with the particular goal 
to preserve renal function”.
Role of kidney biopsy in the management 
of Fabry nephropathy
As previously mentioned, the role of kidney biopsy in 
new case discovery cannot be overemphasized. Even 
though Fabry disease may not have been considered in the 
differential diagnosis of a patient with CKD and proteinuria, 
The typical manifestations of Fabry nephropathy on biopsy Biologics: Targets & Therapy 2008:2(4) 833
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are well described and readily appreciated, so the diagnosis 
should be readily discerned (Gubler et al 1978; Sessa et al 
2002; Fervenza et al 2008).
In patients with a pre-established diagnosis of Fabry 
disease, there can still be an important role for kidney biopsy 
for assessing burden of disease, and assisting in problematic 
cases with decisions about when to initiate ERT, and con-
ceivably dosing or frequency decisions (Ortiz et al 2008). It 
is too dogmatic to insist that every patient have a baseline 
biopsy, but several issues that need to be kept in mind. It is 
clear from the placebo-controlled trials with both forms of 
ERT, that patients with less severe “burden of disease” will 
do better on ERT than those with more advanced disease. 
There is no consensus, at present on the speciﬁ  c measures 
that should be included in the assessment of burden of 
disease, but likely factors would include decreased kidney 
function, proteinuria, pathologic changes on kidney biopsy, 
the extent and severity of GL-3 deposits. The magnitude of 
the baseline proteinuria (Banikazemi et al 2007; Germain 
et al 2007; Schiffmann et al 2007), the baseline level of GFR, 
and other conventional risk factors, such as hypertension, 
gender, smoking, and hypercholesterolemia have an impact 
on the burden of disease and rate of progression.
There are other progression factors that have not yet been 
deﬁ  ned. Kidney biopsy would seem to be worthwhile in such 
patients who have rapid progression without obvious risk 
factors for that progression. Based on the phase III results 
(Germain et al 2007), patients who have signiﬁ  cant focal 
glomerulosclerosis and sclerosis are likely to progress quite 
rapidly. A similar ﬁ  nding was reported by Branton et al in 
which there appears to be a strong association between the 
baseline glomerulosclerosis scores, and the level of baseline 
proteinuria and GFR (Branton et al 2002). Even in young 
children, deﬁ  nite renal pathology has been described even 
in those who have not yet developed overt proteinuria or 
decreased GFR (Tondel et al 2008). In such cases, the kidney 
biopsy ﬁ  ndings would favor institution of ERT rather than 
waiting for clinically evident target organ damage if the 
process is already established at the level of the biopsy.
It is essential that adequate tissue be obtained with 
sufﬁ  cient number of glomeruli to assess overall involvement, 
including extent of focal and global glomerular ﬁ  brosis and 
sclerosis, and tubulo-interstitial ﬁ  brosis on light microscopy, 
and the extent of GL-3 deposits on the thin sections and 
electron microscopy (Valbuena et al 2008). While the typical 
“Zebra bodies” seen in podocytes on electron microscopy 
should lead to the correct diagnosis, the utility of scoring of 
the extent and severity of renal involvement are emerging as 
important factors in assessing prognosis and response to ERT 
and other therapies (Valbuena et al 2008). An international 
effort has been mounted to validate such a scoring system, 
with the hopes that it will be useful for describing the severity 
of disease and even response to therapy (Oliveira 2007).
Occasionally, there have been suggestions that ERT 
doses higher than 1 mg/kg might have some utility in treating 
refractory cases of Fabry nephropathy. There is simply not 
any evidence to support this proposal, especially considering 
the additional costs of what is already very expensive therapy. 
The results in Figures 4 and 5 suggest an approach that could 
be applied when ERT at doses greater than 1 mg/kg every 
2 weeks is being considered. A kidney biopsy should be 
undertaken at this point (Ortiz et al 2008). There could be 
another form of kidney disease superimposed upon Fabry 
nephropathy that obviously would not respond to increased 
ERT, and in addition, if the biopsy demonstrates complete 
clearance of glomerular capillary endothelial GL-3 deposits, 
such as in Figure 7, then there does not appear to be any 
current justiﬁ  cation for using a higher or more frequent 
dose of ERT. In contrast, the cases shown in Figure 6 had 
incomplete GL-3 endothelial clearance, and these patients 
were subsequently treated with higher doses of ERT than they 
received during their initial treatment period. This approach 
assumes that glomerular capillary endothelial GL-3 deposits 
are an acceptable marker for the burden of disease in Fabry 
nephropathy, an attractive hypothesis that has not yet been 
validated.
Proteinuria and progression
of Fabry nephropathy
These reports do not establish an optimal dose for ERT in 
patients with moderately severe Fabry nephropathy, but are 
consistent with the hypothesis that proteinuria  1 g/day is 
a major risk factor for progression regardless which dose or 
preparation is used. There may be additional factors, besides 
baseline eGFR and proteinuria, that drive progressive loss 
of kidney function, and need to be identiﬁ  ed before the 
optimal dose and interval for ERT can be deﬁ  ned. Three 
reports have described patients with relatively low levels of 
baseline proteinuria ( 0.5 g/day) before ERT was initiated; 
these reports are consistent with a possible effect of dose or 
frequency of dosing of ERT on the progression rate (Table 1). 
In the single case reported by Warnock (2005), the urine 
protein excretion was controlled with ACEI/ARB therapy 
before agalsidase-alfa was started. During the 16-month 
agalsidase-alfa treatment period, the eGFR decreased at a rate 
of −13.7 mL/min/1.73 m2/year (Figure 5). Four patients from Biologics: Targets & Therapy 2008:2(4) 834
Fervenza et al
the Fabry Outcomes Survey Registry have been described 
with similar degrees of proteinuria during ERT (222.8 ± 
60 [SEM] mg/day) who progressed at −5.0 ± 4.08 mL/
min/1.73 m2 per year on 0.2 mg/kg agalsidase-alfa given 
every 2 weeks (Patients 7, 10, 12 and 14; Table 5 [Schwart-
ing et al 2006]). Schiffman et al (Schiffmann et al 2007) 
described 4 patients with low baseline proteinuria who 
progressed rapidly on 0.2 mg/kg agalsidase-alfa given every 
other week. The weighted average rate of progression for 
this group of 9 patients with low baseline proteinuria was 
−6.69 ± 2.90 (SD) mL/min/1.73 m2/year over a 27.6 month 
follow-up period. Table 1 also presents the data for 
58 patients with low baseline proteinuria who received larger 
or more frequent doses of ERT than the 9 patients shown 
in the top section of Table 1. The weighted average rate of 
progression for the group of 58 patients with low baseline 
proteinuria was −0.97 ± 2.10 (SD) mL/min/1.73 m2/year 
over a 45.2 month follow-up period. While these are 
simply open-label, uncontrolled observational studies, the 
results are consistent with the thesis that there is a subset of 
Fabry patients with low grade proteinuria who will continue 
to progress on agalsidase-alfa given at 0.2 mg/kg every 
other week, and who beneﬁ  t by increasing the dose and/or 
frequency of ERT administration. It is work noting that the 
patient described by Warnock (Warnock 2005) and those 
described by Schiffman et al (2007) had slowing of their 
progressive loss of GFR when the ERT dose or frequency 
was increased above 0.2 mg/kg given every other week.
The importance of overt proteinuria as a major risk factor 
for progressive loss of kidney function was emphasized in 
the report of treatment outcomes from Würzburg (Breunig 
et al 2006), and proteinuria, as well as glomerular sclerosis 
and reduced baseline GFR were emphasized as risk factors 
for progression in the 54-month open label extension study 
of the Phase III study with agalsidase-beta (Germain et al 
2007). Those patients who did not have overt proteinuria or 
signiﬁ  cant glomerulosclerosis at baseline biopsy did quite 
well on ERT, while those with overt proteinuria ( 1 g/day) 
and/or glomerular ﬁ  brosis or sclerosis in 50% of their glom-
eruli did not beneﬁ  t from ERT at 1 mg/kg every 2 weeks 
(Germain et al 2007). Whether their outcome would have 
been improved if their proteinuria had been controlled with 
ACEI/ARB therapy is the subject of current investigation.
Proteinuria has emerged as a major determinant in 
the development of progressive tubular injury, interstitial 
ﬁ  brosis, and GFR loss in CKD (Remuzzi et al 2006), as well 
as Fabry nephropathy (Schiffmann 2007; Warnock 2007). 
Higher baseline levels of proteinuria are associated with 
more rapid decline of renal function (Breunig et al 2006; 
Banikazemi et al 2007; Germain et al 2007; Schiffmann 
et al 2007). The relationship between baseline proteinuria 
and the future occurrence of adverse kidney outcomes, 
even in patients with relatively mild Fabry nephropathy is 
depicted in Figure 9. At the initial assessment, the ﬁ  nding of 
signiﬁ  cant proteinuria is a call for action, both for institution 
of effective ERT and control of proteinuria with ACEIs and 
ARBS. Elevated urinary protein excretion is a common ﬁ  nd-
ing in Fabry disease (Figure 1), and along with measurement 
of serum creatinine and calculation of eGFR, are integral 
elements of the clinical assessment of Fabry nephropathy 
(Ortiz et al 2008).
Four other patients have been described in the FOS Registry 
with marked degrees of proteinuria (2.9 ± 1.5 [SEM] g/day) but 
slow rates of progression (0.38 ± 1.52 mL/min/1.73 m2 per year) 
on 0.2 mg/kg agalsidase-alfa given every 2 weeks (Patients 
1, 4, 17 and 20; Table 5 (Schwarting et al 2006)). This ﬁ  nding 
is at odds with all other reports of Fabry patients with similar 
baseline levels of GFR on any form of ERT who did not receive 
sufﬁ  cient ACEI/ARB therapy to lower urine protein excretion 
to less than 1 g/day (Breunig et al 2006; Banikazemi et al 2007; 
Germain et al 2007; Schiffmann et al 2007).
The long-term results (54 months) for 58 patients who 
completed the phase III study of agalsidase-beta have 
recently been described. Following the initial 20-week 
double-blind phase, all 58 patients were transitioned to an 
open-label extension study, and received agalsidase-beta 
at 1 mg/kg every other week for as long as an additional 
54 months (Germain et al 2007). Median serum cre-
atinine and eGFR were relatively unchanged at the end 
of 54 months of open-label therapy for 42 patients whose 
baseline proteinuria was less than 1 g/day. The initial eGFR 
averaged 138 mL/min/1.73 m2, and the mean progres-
sion rate (eg, loss of eGFR) was −1.005 ± 0.970 [SEM] 
mL/min/1.73 m2/year (Figure 10). In contrast, 10 patients 
had rapid progression (rate = −7.399 ± 1,858 [SEM] 
m:/min/1.73 m2/year) despite relatively normal eGFR at 
baseline (average = 100 mL/min/1.73 m2). Two charac-
teristics separated those with rapid progression from the 
majority who did not progress: the baseline proteinuria 
exceeded 1 g/day and the kidney biopsies revealed focal or 
global glomerular sclerosis in at least 50% of the glomeruli 
(Germain et al 2007).
It needs to be emphasized that ERT, by itself, has not 
been shown to reduce proteinuria in Fabry nephropathy. The 
phase III agalsidase-beta trial (Wilcox et al 2004) showed 
that the patients with overt proteinuria did not have any effect Biologics: Targets & Therapy 2008:2(4) 835
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Figure 9 Relationship between baseline proteinuria and probability of a renal outcome event in the phase III extension study. Baseline proteinuria (expressed as the urinary 
protein/creatinine ratio) was determined before entry into the double-blinded initial phase of the study. Logistic regression analysis was used to determine the probability of a 
renal event (deﬁ  ned as 50% increase in serum creatinine compared to pre-treatment value, with the increased value  1.4 mg/dL). Adapted with permission from Germain D, 
Waldek S, Banikazemi M, et al 2007. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol, 18:1547–57. 
Copyright © 2007 American Society of Nephrology.
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Figure 10 Relationship between baseline proteinuria and the rate of loss of estimated glomerular ﬁ  ltration rate (eGFR) in the phase III extension study.   The participants 
were sub-grouped based on their baseline proteinuria, which was determined before entry into the double-blinded initial phase of the study. During the 54-month treatment 
period, patients (n = 10) with baseline urinary protein/creatinine ratios   1.0 had a mean rate of decline of eGFR of −7.4 mL/min/1.73 m2/year. In contrast, patients (n = 42) 
with baseline urinary protein/creatinine ratios   1.0 had a mean rate of decline of eGFR of −1.0 mL/min/1.73 m2/year. Adapted with permission from Germain D, Waldek 
S, Banikazemi M, et al 2007. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol, 18:1547–57. 
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of ERT on their level of proteinuria, and some patients with 
modest amounts of proteinuria at baseline developed overt 
proteinuria despite ERT. Similar results have been reported 
in the phase III extension study (Germain et al 2007), and 
in open label studies (Breunig et al 2006; Schiffmann et al 
2006; Schiffmann et al 2007).
Previous studies had reported the use of ACEIs and/or 
ARBs in Fabry patients with proteinuria, but without any 
systematic approach to reduction of urinary protein excretion 
to a speciﬁ  c target (Wilcox et al 2004; Breunig et al 2006; 
Schiffmann et al 2006; Germain et al 2007; Schiffmann 
et al 2007). Because of the limited effect of ERT on slow-
ing progression of Fabry nephropathy in patients with overt 
proteinuria at baseline, and the realization that the early 
success described in moderately severe Fabry nephropathy 
(Figure 2) was accompanied by the use on an ARB to control 
urine protein excretion, the systematic use of antiproteinuric 
therapy with ACEIs and/or ARBs was undertaken in a long-
term open-label study of 10 patients (Tahir et al 2007). The 
study patients would historically have been at high risk for 
progressive loss of kidney function according to the phase III 
and phase IV results: baseline eGFR  60 mL/min/1.73 m2, 
and baseline urine protein excretion  1 g/day. When urine 
protein excretion was controlled to a target of  0.5 g/day 
by carefully titrating ACEI and ARB doses in these adult 
Fabry patients who were also treated with agalsidase-beta 
at 1 mg/kg every other week, the rate of loss of eGFR was 
not signiﬁ  cantly different than zero (Tahir et al 2007). There 
was a decrease in blood pressure in these patients treated with 
anti-proteinuric therapy, which can limit dosing of ACEIs and 
ARBs. Fortunately, the doses required to control proteinuria 
in these patients were relatively modest (Tahir et al 2007). 
Although only observed in 6 patients, the slowing of progres-
sive eGFR loss was much better than reported in the phase 
IV study for a similar group of patients with overt proteinuria 
and eGFR   60 mL/min/m2 (Breunig et al 2006; Schiffmann 
et al 2006; Banikazemi et al 2007; Schiffmann et al 2007). In 
these previous series, the importance of baseline proteinuria 
was recognized, and a number of patients were treated with 
ACEI or ARB therapy, but there was not any systematic 
attempt to titrate the dose to achieve a targeted reduction in 
urine protein excretion to  0.5 g/day.
Titration of urine proteinuria
with anti-proteinuric therapy
Data from the RENAAL study shows that the renal 
protective effect of losartan in Type II diabetic nephropathy 
was nearly fully explained by its anti-proteinuric effect 
(Keane et al 2003; Eijkelkamp et al 2007). In both diabetic 
and nondiabetic patients with CKD, ACEIs and ARBs 
reduce proteinuria and slow progression, and are also car-
dio-protective (Mann et al 2008; ONTARGET 2008). It has 
long been appreciated that the degree of renal protection is 
related to the immediate reduction in proteinuria (GISEN 
1997). The future rate of decline of GFR In patients with 
Fabry disease can be predicted from the baseline proteinuria 
at the time of initiation of ERT if urine protein excretion is 
not controlled (Figure 9). ERT alone will not reduce overt 
proteinuria in Fabry disease (Wilcox et al 2004; Banikazemi 
et al 2007; Germain et al 2007; Schiffmann 2007; Schiff-
mann et al 2007; Warnock 2007), but maintenance of urine 
protein excretion at  0.5 g/day with ACEI/ARB therapy has 
been shown to stabilize eGFR in patients with moderately 
severe Fabry nephropathy who are receiving agalsidase-
beta at 1 mg/kg every 2 weeks (De Schoenmakere et al 
2003; Tahir et al 2007). Blood pressure is usually normal in 
Fabry patients (Wilcox et al 2004; Banikazemi et al 2007; 
Germain et al 2007; Schiffmann et al 2007; Tahir et al 
2007). Thus, titration of anti-proteinuric agents is needed 
to the proteinuria target, rather than a systemic blood pres-
sure target. Both telmisartan and ramipril were shown to 
slow progression in the ONTARGET Study, but worsened 
renal outcome when used in combination (Mann et al 2008). 
However, ONTARGET was a ﬁ  xed-dose, forced titration 
study in patients with relatively modest proteinuria, while 
the approach proposed for Fabry nephropathy is titration of 
the proteinuria to a ﬁ  xed target of 500 mg/day. The hope 
is that ACEI and/or ARB therapy, together with optimal 
dosing of ERT will stabilize kidney function in patients with 
Fabry nephropathy, a clear-cut improvement over what has 
been reported in previous studies of Fabry patients who are 
at high risk of progressing to ESRD (Wilcox et al 2004; 
Breunig et al 2006; Banikazemi et al 2007; Germain et al 
2007; Schiffmann et al 2007).
It appears that control of urine protein excretion is 
important in Fabry nephropathy, and that the optimal response 
to ERT requires the use of anti-proteinuric therapy to reduce the 
urine protein to a target of  0.5 g/day. This hypothesis is being 
tested in an ongoing, open-label, prospective multi-center 
observational trial that is called the FAACET Study (FAACET 
2007); 40 patients with moderate to moderately severe Fabry 
nephropathy and overt proteinuria will be enrolled and fol-
lowed for 24 months on combined therapy with agalsidase-beta 
at 1 mg/kg given every 2 weeks, and systematic titration of 
ACEI/ARB therapy to reduce urine protein to  500 mg/day. 
It would be of great interest to see if a similar stabilization Biologics: Targets & Therapy 2008:2(4) 838
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of eGFR would be observed in high risk Fabry patients with 
baseline eGFR   60 mL/min/1.73 m2 and baseline protein-
uria  1 g/day who were treated with ACEI/ARB therapy to a 
target urine protein excretion of  500 mg/day while receiving 
agalsidase-alfa at 0.2 mg/kg every 2 weeks.
Anti-agalsidase antibodies
and the effectiveness of ERT
The immunogenicity of infused exogenous agalsidase, and 
the subsequent generation of anti-agalsidase antibodies 
explains the infusion reactions that can occur after initiation 
of ERT in males who have no residual alpha-galactosidase 
activity. Such Infusion-associated events (rigors, fever, 
myalgias) are related to infused dose and infusion rate, 
but rarely can be attributed to true IgE-related anaphylaxis 
(Schiffmann et al 2001; Wilcox et al 2004; Banikazemi 
et al 2007). Even with severe reactions, it now appears 
possible to de-sensitize patients who develop IgE responses 
to agalsidase-beta (Bodensteiner et al 2008).
Antibody responses against agalsidase are rarely 
encountered in females, who generally have some circulating 
enzyme and residual alpha-galactosidase A activity (Fuller 
et al 2004). If they do develop anti-agalsidase antibodies, the 
titers are generally low, and in the long run, they appear to 
become tolerant to ERT (Banikazemi et al 2007). There may 
also be an effect of the underlying mutation; entire deletions 
and early stop-codons result in the absence of circulating gene 
product. On the other hand, mis-sense deletions or frame-shifts 
can result in circulating proteins that may have native native 
alpha-galactosidase A sequence in the N-terminus, while the 
rest of the protein is unrelated to the native protein. Most male 
patients with Fabry disease are negative for cross-reacting 
immunologic material (CRIM) (Wilcox et al 2004). Patients 
who are CRIM-positive do not appear to have immunologic 
reactions if their mutations do not impair antigen presentation 
during the development of self-tolerance during the late fetal 
and post-natal period (Kyewski and Klein 2006).
Despite differences in glycosylation that could affect 
tissue delivery and uptake (Lee et al 2003), agalsidase-alfa 
and agalsidase-beta appear have identical immunogenicity 
and speciﬁ  c activity (Lee et al 2003; Linthorst et al 2004). 
There is a single report from Japan describing markedly 
reduced speciﬁ  c enzyme activity of agalsidase-alfa compared 
with agalsidase-beta (Sakuraba et al 2006), but this ﬁ  nding 
has not been conﬁ  rmed by other reports.
In vitro studies have shown that anti-agalsidase antibodies 
can exhibit neutralizing capacity towards the infused enzyme. 
In addition, there is accumulating evidence in a number 
of lysosomal storage disorders that antibodies generated 
against infused recombinant enzyme can also interfere 
with mannose-6-phosphate-mediated receptor uptake, even 
though the antibodies may not affect the speciﬁ  c activity 
of the enzyme. Thus, there are two distinct mechanisms 
that can impair the effectiveness of infused enzyme (Wang 
et al 2008). In vivo, patients with anti-agalsidase IgG have 
blunted urinary GL-3 clearance, as compared to those who 
remain antibody-negative (Linthorst et al 2004; Whitﬁ  eld 
et al 2005). The prevalence and titers of anti-agalsidase 
antibodies do not differ between patients treated with 
different doses (0.2 mg/kg versus 1.0 mg/kg body weight 
every 2 weeks) of ERT or in patients switched from lower 
to higher doses of ERT (Vedder et al 2008).
The issue of antibody titers was addressed in a recent 
study that compared the two different preparations of ERT 
(either agalsidase-alfa or agalsidase-beta at 0.2 mg/kg every 
2 weeks) versus agalsidase-beta at 1.0 mg (Vedder et al 
2008). There were no signiﬁ  cant differences in the prevalence 
of neutralizing antibodies in patients treated with 0.2 mg/kg 
of agalsidase-alfa compared to agalsidase-beta, or in patients 
treated with 0.2 mg/kg of agalsidase-beta compared with 
1 mg/kg agalsidase-beta (Vedder et al 2008). More complete 
clearance of plasma and urinary GL-3 in male patients treated 
with the 1.0 mg/kg agalsidase-beta was observed than in those 
treated with either preparation at 0.2 mg/kg every 2 weeks. 
Of note, the reduction in left ventricular mass was similar 
in antibody-positive and antibody-negative patients, as long 
as they were treated with ERT at 1 mg/kg every 2 weeks 
(Vedder et al 2008).
These results have been criticized (Mehta et al 2008) 
for the small number of patients, and for pooling the results 
for patients treated with 0.2 mg/kg agalsidase-alfa with the 
results for patients treated with 0.2 mg/kg agalsidase-beta. 
It was asserted that the two ERT preparations not identi-
cal, despite the previous reports that the two preparations 
have identical immunogenecity (Lee et al 2003; Linthorst 
et al 2004). The assessment of cardiac improvement was 
limited to measurements of left ventricular mass, without 
clear-cut reference to baseline values or improvement in 
other measures of cardiac function. Urinary clearance of 
GL-3 was impaired in antibody-positive patients treated with 
0.2 mg/kg ERT, conﬁ  rming previous observations (Linthorst 
et al 2004; Schiffmann et al 2006), but this ﬁ  nding has not 
been shown to correlate with any differences in clinical 
outcomes in prospective studies. In fact, kidney function 
remained stable for 12 months in all of the treatment groups 
in the study (Vedder et al 2008).Biologics: Targets & Therapy 2008:2(4) 839
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In vitro studies in mice with sera from anti-agalsidase 
antibody-positive patients (Ohashi et al 2008; Vedder et al 
2008). and in vivo studies in patients (Vedder et al 2008) sug-
gest that the potential neutralizing effects of anti-agalsidase 
antibodies may be overcome by increasing the dose or ERT 
from 0.2 to 1.0 mg/kg. It is not known whether the effects or 
titers of anti-agalsidase neutralizing IgG antibodies correlate 
with long-term clinical outcomes, but this point clearly needs 
to be addressed. The increase in urinary GL-3 excretion 
above baseline in antibody-positive patients treated with 
ERT at 0.2 mg/kg every other week only became apparent 
after 6 months of infusion therapy, was not correlated with 
infusion-related reactions. No information is available about 
doses other than 0.2 or 1.0 mg/kg ERT, or for dosing intervals 
other than every other week. For now, it would seem prudent 
to regularly monitor urinary GL-3 excretion, especially in 
patients treated with ERT at 0.2 mg/kg every 2 weeks. If 
there is a progressive rise in urinary GL-3 excretion after 
several months of ERT, then consideration should be given to 
increasing the frequency of monitoring of clinical outcomes. 
If there is any subsequent indication of decreasing eGFR, or 
increasing proteinuria, then increasing the dose of ERT to 
1 mg/kg every other week could be considered. If there are 
continuing and severe infusion-related reactions, then de-sen-
sitization (Bodensteiner et al 2008), or even induction of 
tolerance (Wang et al 2008) may be worthwhile. Increasing 
urinary GL-3 excretion has not been associated with any 
adverse clinical outcome at this time; more work is required 
to understand the clinical signiﬁ  cance of this ﬁ  nding, and to 
determine if urinary GL-3 excretion can serve as a useful 
biomarker that is related to the whole body disease burden 
and responses to therapies.
ERT in special populations
Pediatric patients with Fabry disease
The mean age of symptom onset of Fabry disease has been 
reported to be 10 years in boys and 15 years in girls, with 
cases presenting as early as 3 years in boys and 6 years in 
girls, and renal failure developing as early as 16 years of age 
in boys (MacDermot et al 2001; Ries et al 2003; Desnick 
and Brady 2004; Ries et al 2006). In the Fabry Outcome 
Survey database, 8 patients had albuminuria and 12 patients 
had proteinuria from a total of 82 patients younger than 
18 years (Ramaswami et al 2006). A recent report from the 
Fabry Registry of 352 pediatric patients (age  18 years) 
described 2 children with Stage 2 CKD, and 1 child with 
stage 3 CKD, indicating that some Fabry patients develop sig-
niﬁ  cant nephropathy during childhood (Hopkin et al 2008). 
Twenty-four hour urine assessments were available in 
86 patients; 4 males and 5 females had urinary protein excre-
tion  150 mg/24 h. Four additional patients (3 males and 
1 female) had albumin excretion rates  30 mg/24 h among 
the 46 patients for whom these data were available.
In contrast to the well-described kidney biopsy ﬁ  ndings in 
adult patients, there is limited information concerning renal 
morphological changes in young patients with Fabry disease. 
Renal GL-3 deposits have been described as early as the ﬁ  rst 
5 months of pregnancy (Brady et al 1971; Elleder et al 1998). 
GL-3 deposits were described in renal biopsies from 3 chil-
dren aged 8 (female), 11, and 12 years (males), all without 
proteinuria (Gubler et al 1978); GL-3 deposits were detected 
at an early age in vessels and glomeruli in male patients, 
whereas the distribution of GL-3 deposits was more irregular 
in female patients (Gubler et al 1978). A series was reported 
of kidney biopsies in 7 male and 2 female pediatric patients 
with a mean age of 13.5 years (range, 7 to 18 years); biopsies 
were performed before the start of ERT in 7 patients, and 
after 2 years of ERT in 2 patients (Tondel et al 2008). In all 
patients, light and electron microscopy showed severe GL-3 
accumulation in podocytes. A conspicuous and worrisome 
ﬁ  nding was the presence of hyaline deposits in the media 
of small renal arteries in nearly half (4 of 9) these pediatric 
patients who underwent biopsy before they developed overt 
clinical ﬁ  ndings of Fabry nephropathy (Tondel et al 2008).
In these biopsy studies, signiﬁ  cant deposition of GL-3 
was found in glomeruli, as well as the tubulo-interstitial and 
vascular compartments long before overt Fabry nephropathy 
was manifested clinically (Gubler et al 1978; Tondel et al 
2008; Valbuena et al 2008). These observations demonstrate 
that albuminuria or overt proteinuria are not reliable early 
predictors of Fabry nephropathy since glomerulosclerosis 
as well as signiﬁ  cant tubulo-interstitial ﬁ  brosis can occur 
before overt proteinuria or signiﬁ  cant loss of kidney func-
tion occurs. While there is ongoing debate about the optimal 
timing for initiating ERT, especially in pediatric patients, 
the recent biopsy studies argue against waiting until there is 
demonstrated kidney damage as evidenced by reduced eGFR 
or overt proteinuria before initiating ERT.
There are important concerns about the accurate 
measurement of GFR in Fabry patients. In the recent study 
from the Fabry Registry (Hopkin et al 2008), the majority 
of children had estimated GFR values (using the Schwartz 
formula) that were higher than expected for healthy children 
and adolescents of the same age. The study by Tøndel et al 
supports these observations in that there was a signiﬁ  cant 
increase in eGFR when compared with iohexol-GFR in all Biologics: Targets & Therapy 2008:2(4) 840
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patients in the study group (Tøndel et al 2008), a ﬁ  nding that 
has been referred to as “hyperﬁ  ltration” (Rodriguez-Iturbe 
et al 1985). Clearly, accurate and validated measurements of 
GFR are needed, especially in children if this information is 
going to be used as a criterion for initiating ERT or following 
the response to ERT in the individual patient.
There are very few studies of the effects of ERT in pedi-
atric populations. Ries et al conducted a prospective study of 
ERT for 6 months in 24 children (mean age, 11.8 years; range, 
6.5–18 years) and showed that treatment was safe and well 
tolerated (Ries et al 2006). In this study, renal hyperﬁ  ltration 
was corrected, albuminuria decreased in 3 of 4 subjects, and 
heart rate variability improved, indicating that there may be a 
“window of opportunity” to correct early organ damage and 
prevent progressive disease with early initiation of ERT (Ries 
et al 2006). Similarly, in the study by Tøndel et al electron 
microscopy showed glomerular endothelial GL-3 inclusions, 
in all patients except the 2 boys treated with agalsidase-alfa 
at 0.2 mg/kg every 2 weeks for 2 years (Tondel et al 2008). 
On the other hand, these two boys developed de novo albu-
minuria, glomerulosclerosis, interstitial ﬁ  brosis and podocyte 
GL-3 deposits, while they were being treated with ERT at a 
dose of 0.2 mg/kg (Tondel et al 2008).
Wraith et al described 14 male and 2 female patients, 
8 to 16 years old, who received an open-label 48-week 
course of agalsidase-beta at 1 mg/kg infused intravenously 
every 2 weeks (Wraith et al 2008). ERT was shown to reduce 
GL-3 accumulation in dermal endothelium in children with 
Fabry disease (Wraith et al 2008). Mild proteinuria, deﬁ  ned 
as  100 mg/m2/24 h for pediatric patients (Hogg et al 2000), 
was seen in 8 of 15 patients at baseline, and 3 of the 8 patients 
had values  100 mg/m2/24 h at week 48. Mean eGFR was 
126 ± 29 (SD) mL/min/1.73 m2 at baseline (n = 16), and 
125 ± 26 (SD) at week 48 (n = 15). For the 3 adolescent male 
patients with possible hyperﬁ  ltration and mild proteinuria 
at baseline, further deterioration of renal function was not 
observed during the 48 months of follow-up. The overall 
safety proﬁ  le for agalsidase-beta in pediatric patients is similar 
to that observed in adult patients (Eng et al 2001; Banikazemi 
et al 2007; Germain et al 2007; Wraith et al 2008).
The pediatric studies published to date have not included 
enough patients with sufﬁ  cient long-term follow up to determine 
whether early initiation of ERT can prevent the development of 
irreversible target-organ damage, or just slow the progression of 
disease. Prospective treatment trials and long-term monitoring 
of a signiﬁ  cant number of patients are required to determine 
the impact of ERT on this group of patients. An ongoing 
open-label study (FIELD 2008) is currently examining the use 
of agalsidase-beta given at 1 mg/kg every 4 weeks compared 
to 0.5 mg/kg given every 2 weeks in a group of 24 males less 
than 18 years of age with minimal symptoms; the primary out-
come measure is clearance of GL-3 deposits in dermal vascular 
endothelial cells. The secondary outcome measures include 
reductions in plasma and urinary GL-3 levels.
Kidney transplant recipients
with Fabry disease
ESRD in Fabry disease can be successfully managed by 
kidney transplantation (Ojo et al 2000). The pharmacokinetics 
of agalsidase-alfa is the same in transplant patients as in 
Fabry patients with native kidneys (Pastores et al 2007). 
The detection of Fabry patients among dialysis and trans-
plant patients is important because of organs other than 
the kidneys are involved in Fabry disease. The hope is 
that ERT treatment may ameliorate symptoms or prevent 
further progression of cardiovascular and cerebrovascular 
complications in these patients. A pilot study reported 
improvement in left ventricular hypertrophy and ejection 
fraction in 3 Fabry patients who had been transplanted and 
were treated with agalsidase-beta at 1 mg/kg every other 
week (Mignani et al 2004). These preliminary ﬁ  ndings have 
been extended and conﬁ  rmed in a larger group of patients 
transplanted with an average follow-up of 48 months on ERT 
after kidney transplantation (Mignani et al 2008).
ERT in dialysis patients
Administration of ERT during hemodialysis is not associated 
with a reduction of the enzyme activity or enzyme loss into 
the dialysate of agalsidase-alfa (Pastores et al 2007), or 
agalsidase-beta (Kosch et al 2004). Agalsidase-beta given 
to Fabry ESRD patients on hemodialysis was associated 
with improvement in pain and gastrointestinal symptoms, 
and halved the rate of progression of left ventricular mass 
index compared with the rate before institution of ERT 
(Pisani et al 2005), although there is a suggestion that the 
cardiac response to ERT may not be quite as favorable in 
Fabry patients on dialysis as has been described in Fabry 
patients who have received kidney transplants (Mignani 
et al 2008).
Conclusions and pending issues
While the “classical” presentation of Fabry disease is well 
described (Desnick et al 2001; Branton et al 2002), there 
are patients who have serious organ involvement without 
all of the classical ﬁ  ndings. The phenotypic variation in 
females, and even among family members with the same Biologics: Targets & Therapy 2008:2(4) 841
ERT and Fabry nephropathy
AGAL mutation is notable; additional work is needed to 
better deﬁ  ne the basis for this variation. The appreciation of 
the wider spectrum of disease than is described by the clas-
sical phenotype is important since the clinical diagnosis may 
not be apparent in patients who lack the typical signs and 
symptoms of Fabry disease, and for whom the appropriate 
diagnostic testing is not carried out.
The advent of ERT has transformed Fabry disease into a 
treatable cause of proteinuric CKD. However, some issues 
need to be addressed:
•  The general applicability of anti-proteinuria therapy in the 
context of ERT therapy for Fabry nephropathy needs to 
be conﬁ  rmed and extended to a large cohort of patients. 
Both the optimal target for urine protein reduction, and 
the optimal dose of ERT in patients who have had their 
proteinuria reduced to that target, need to be deﬁ  ned.
{  In patients with baseline proteinuria  1 g/day, the 
prospects need to be determined for stabilization of 
kidney function with approved doses of agalsidase-
alfa or agalsidase-beta plus titration of proteinuria 
to less than 500 mg/day with ACEI/ARB therapy.
{  In patients with baseline proteinuria  1 g/day, the 
prospects need to be determined for stabilization 
of kidney function with approved doses of agalsi-
dase-alfa or agalsidase-beta plus minimization of 
proteinuria with ACEI/ARB.
•  The therapeutic beneﬁ  ts of ERT on cerebrovascular 
and cardiovascular events remain to be demonstrated in 
outcome studies that are not dominated by the occurrence 
of renal events. Transplant and dialysis patients, and 
patients in whom kidney function has been stabilized with 
ERT and control of proteinuria with ACEI/ARB therapy 
would be appropriate subjects for these prospective 
studies.
•  Just as anti-proteinuric therapy appears to be important 
adjuncts for ERT in Fabry nephropathy, the usefulness 
of similar adjuncts to ERT for the cardiovascular and 
cerebrovascular manifestations of Fabry disease need to 
be explored. It is notable that some Fabry patients who 
have had stabilization of their kidney function on ERT can 
still develop cardiovascular complications of the disease, 
so ACEI/ARB therapy may not be as cardio-protective 
in Fabry patients as in other patient cohorts.
•  The optimal timing of initiation of ERT before irreversible 
organ damage has occurred needs to be addressed.
The available evidence strongly supports the provision 
of ERT for Fabry nephropathy, even though the current 
expectation is to halt progression of disease, rather than 
any actual resolution of pre-existent organ damage. Rather 
than being a criticism to the effectiveness of ERT in Fabry 
nephropathy, it should be recognized that this limitation 
exists for all forms of CKD, emphasizing the importance 
of surveillance, early detection and close monitoring of 
burden of disease and progression of organ involvement as 
important contributors to the ultimate success of treating 
these diseases.
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